Apimeds Pharmaceuticals US Total Current Liabilities

Apimeds Pharmaceuticals US (APUS) currently reports a total current liabilities of $15M as of March 2026. That compares with $1.8M in the prior-year period — up 723.8% year over year. Use the charts on this page to explore Apimeds Pharmaceuticals US's total current liabilities history and peer comparisons.

Apimeds Pharmaceuticals US's total current liabilities increased from $1.8M to $15M — a 723.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $15M in total current liabilities as of March 2026. That compares with $1.8M in the prior-year period — up 723.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.